

Alcidion Group Limited (ABN 77 143 142 410)

Appendix 4D

& Financial statements for the period ended 31 December 2023

Results for announcement to the market

Reporting Periods

Current reporting period	Half-year ended 31 December 2023
Previous reporting period	Half-year ended 31 December 2022

Key information

		% Change		\$000
Total revenue from ordinary activities	Up	0.4%	to	19,059
Loss from ordinary activities after tax attributable to members	Up	52.6%	to	(4,336)
Net loss for the period attributable to members	Up	52.6%	to	(4,336)

Details relating to dividends

No dividends were paid or proposed for the current or previous corresponding half-year period.

Explanation of results

First half revenue at \$19,059K was marginally ahead of prior corresponding period (PCP).

The business saw an increase in gross profit percentage to 88% and an overall increase in gross profit of \$400K compared to the PCP. This was offset by a planned increase in staff costs of \$1,667K, comprising full year costs of new hires in prior year and increases to salaries. When combined with the lower-than-expected revenue growth this has led to a \$1,494K (52.6%) increase in the loss from ordinary activities compared to the PCP.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' report and the consolidated financial statements for the half-year ended 31 December 2023 lodged with this document.

Net tangible assets per security

	31 December 2023	30 June 2023
Net tangible assets per security	(\$0.0035)	(\$0.0053)

This Appendix 4D is based on the attached half-year financial report which has been reviewed by the Group's auditors, William Buck. A copy of William Buck's review report is included in the attached half-year financial report.



Alcidion Group Limited

**Financial report for the half year
ended 31 December 2023**

CONTENTS

Directors' Report	1
Auditor's Independence Declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	15
Independent Auditor's Review Report	16
Corporate Directory	18

Directors' Report

The directors submit herewith the financial report of Alcidion Group Limited and its subsidiaries ("Alcidion", "the Group" or, the "Company") for the half-year ended 31 December 2023. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

Directors

The following persons were directors of Alcidion Group Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Ms Rebecca Wilson	Ms Kate Quirke
Mr Simon Chamberlain	Ms Victoria Weekes
Mr Daniel Sharp	

Principal activities

The principal activities of Alcidion include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom.

Review of operations

Operating results

For the half-year period ended 31 December 2023, Alcidion delivered:

- Revenue of \$19,059K a 0.4% increase on the prior corresponding period (PCP) revenue of \$18,984K
- Gross profit of \$16,737K (88%) a 2% increase on the PCP gross profit of \$16,337K (86%)
- A loss after income tax of \$4,336K a \$1,494K (53%) increase on the PCP loss of \$2,842K
- An EBITDA loss of \$2,924K, a \$1,726K increase versus the EBITDA loss in the PCP of \$1,198K

Reconciliation of Loss after tax to non-IFRS EBITDA & underlying EBITDA:

Half-year ended:	31 Dec 2023 \$000	31 Dec 2022 \$000
(Loss) after tax attributable to the owners of the company	(4,336)	(2,842)
<i>Add:</i>		
Depreciation & amortisation expense	1,632	1,542
Income tax expense	-	81
Finance costs	52	64
<i>Less:</i>		
Income tax expense benefit	242	-
Interest revenue	30	43
EBITDA (loss)	(2,924)	(1,198)
<i>Add back:</i>		
Costs related to acquisitions	-	-
Non-cash cost of performance rights	136	132
Underlying EBITDA (loss)	(2,788)	(1,066)

Financial Position

Summary of financial position:

	31 Dec 2023	30 June 2023
	\$000	\$000
Cash and cash equivalents	7,914	14,641
Net current assets	1,677	(295)
Net assets/equity	91,155	90,165
Net tangible assets	(4,677)	(6,668)

Equity

Summary of share capital:

	31 Dec 2023	30 June 2023
Issued capital (\$000)	115,523	110,511
No. of issued shares	1,342,473,221	1,268,069,053
No. performance rights	18,832,852	20,334,755
Share price (\$)	0.075	0.095
Market capitalisation (\$M)	100.7	120.5

Significant contract wins

During the first half of the financial year, Alcidion contracted new sales with a total contract value (TCV) of \$24.3M.

Most notably, in December 2023, the Group signed an extension with South Tees Hospital NHS Foundation Trust for an additional 8 years for the Miya Precision Electronic Patient Record (EPR). The extended contract period is 10 years (to 2033) which includes 2 years remaining on the existing contract. The minimum contract value is \$23.3M (£12.2M) over the new contract period of 10 years. \$20.5M of this extension is included in the new total contract value (TCV) reported in the first half.

A further \$3.8M of new TCV sales were made in the first half which are expected to contribute around \$2.4M revenue to the current financial year. These sales included a new NHS trust in Hampshire Hospitals procuring Miya Precision Emergency module, along with several service extensions and contract renewals.

Likely Developments and Expected Results

As at 31 December 2023, total FY24 contracted revenue is \$35.5M, up 4% on the prior corresponding period. In the absence of larger contract wins (which are progressing but with unpredictable timing), Alcidion expects to achieve second half revenue around the same level as that delivered in the first half.

Recognising continued procurement delays across both the ANZ and UK markets and the need to appropriately balance future growth potential against the current cost base, in Q3 Alcidion will implement annualised costs savings, primarily via the reduction of staff costs, of approximately \$6.4M, resulting from:

- \$2.4M of annualised cost savings realised in the first half of the year; and
- \$4.0M of annualised cost savings, to be implemented during the third quarter

Given the various timings for the cost savings, coupled with restructure and redundancy costs, Alcidion will realise approximately \$2.2M of the proposed costs saving in FY24.

Significant changes in state of affairs

Shares on issue and performance rights:

On 4 September 2023 2,364,226 performance rights vested for \$nil consideration.

On 6 November 2023 67,000,000 shares were issued for \$0.075 by way of an institutional placement.

On 8 December 2023 5,039,942 shares were issued for \$0.075 by way of a share purchase plan (SPP).

On 22 November 2023 the Company issued 7,103,167 performance rights to employees in accordance with the Alcidion Group Limited Equity Incentive Plan.

A further 6,240,844 Performance rights were forfeited and cancelled during the period.

Other than the above, no significant changes in the state of affairs of the Group occurred during the interim period.

Significant Events after the Balance Date

There were no significant events after 31 December 2023.

Dividends

No dividends were paid or declared during the half year and no recommendation for payment of dividends has been made.

Rounding

The Company is a company of the kind referred to in *ASIC Corporations (Rounding in Financials/Directors' Reports) Instruments 2016/191*, dated 24 March 2016, and in accordance with that Corporations Instrument amounts in this directors' report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Auditors Independence Declaration

A copy of the auditor's independence declaration as required under s.307C of the Corporations Act 2001 is set out on page 5.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the Corporations Act 2001.

On behalf of the Directors



Rebecca Wilson
Non-Executive Chair
Melbourne, 28 February 2024

Lead Auditor's Independence Declaration under Section 307c of the Corporations Act 2001

To the Directors of Alcidion Group Limited

As lead auditor for the review of Alcidion Group Limited for the half-year ended 31 December 2023, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Alcidion Group Limited and the entities it controlled during the period.



William Buck (SA)
ABN: 38 280 203 274



G.W. Martinella
Partner

Dated this 28th day of February, 2024.

Statement of profit or loss and other comprehensive income

CONSOLIDATED	Note	31 Dec 2023 \$000	31 Dec 2022 \$000
Revenue		19,059	18,984
Direct costs		(2,322)	(2,647)
Gross Profit		16,737	16,337
Interest income		30	43
Employee benefits expense		(16,273)	(14,606)
Professional fees		(541)	(540)
Marketing expenses		(456)	(407)
Other expenses		(2,391)	(1,982)
Depreciation and amortisation expense	3	(1,632)	(1,542)
Finance costs		(52)	(64)
Loss before income tax expense		(4,578)	(2,761)
Income tax benefit / (expense)		242	(81)
Loss after tax attributable to the owners of the Company		(4,336)	(2,842)
Other comprehensive income/(loss) net of tax <i>Items that may be reclassified subsequently to profit or loss:</i>			
Exchange differences on translation of foreign operations		178	(130)
Total comprehensive loss for the half year attributable to the owners of the Company		(4,158)	(2,972)
(Loss) Per Share			
Basic and diluted loss per share (cents)	8	(0.34)	(0.22)

The notes following the financial statements form part of the financial report.

Statement of financial position

CONSOLIDATED		31 Dec 2023	30 June 2023
	Note	\$000	\$000
Current assets			
Cash and cash equivalents		7,914	14,641
Trade and other receivables	4	8,457	4,735
Other assets		1,279	1,602
Total current assets		17,650	20,978
Non-current assets			
Plant and equipment		555	729
Intangible assets	5	95,832	96,833
Right of use assets		2,006	2,144
Total non-current assets		98,393	99,706
Total assets		116,043	120,684
Liabilities			
Current liabilities			
Trade and other payables		3,600	5,874
Employee provisions		2,644	2,989
Lease liabilities		744	693
Income tax payable		86	108
Unearned revenue		8,899	11,609
Total current liabilities		15,973	21,273
Non-current liabilities			
Employee provisions		125	83
Other provisions		494	494
Deferred tax liabilities		6,965	7,207
Unearned revenue		-	-
Lease liabilities		1,331	1,462
Total non-current liabilities		8,915	9,246
Total liabilities		24,888	30,519
Net assets		91,155	90,165
Equity			
Issued capital	6	115,523	110,511
Share based payment reserves		1,078	942
Foreign currency translation reserve		493	315
Accumulated losses		(25,939)	(21,603)
Total equity		91,155	90,165

The notes following the financial statements form part of the financial report.

Statement of changes in equity

CONSOLIDATED	Issued capital	Share based payment reserves	Foreign currency translation reserve	Accumulated losses	Total equity
	\$000	\$000	\$000	\$000	\$000
Balance as at 1 July 2022	110,511	555	875	(17,986)	93,955
Loss for the period	-	-	-	(2,842)	(2,842)
Other comprehensive income net of tax	-	-	(130)	-	(130)
Total comprehensive income	-	-	(130)	(2,842)	(2,972)
<i>Transactions with owners in their capacity as owners:</i>					
Share-based payment expense	-	132	-	-	132
Balance at 31 Dec 2022	110,511	687	745	(20,808)	91,115
Balance as at 1 July 2023	110,511	942	315	(21,603)	90,165
Loss for the period	-	-	-	(4,336)	(4,336)
Other comprehensive income net of tax	-	-	178	-	178
Total comprehensive income	-	-	178	(4,336)	(4,158)
<i>Transactions with owners in their capacity as owners:</i>					
Share capital issued	5,012	-	-	-	5,012
Share-based payment expense	-	136	-	-	136
Balance at 31 Dec 2023	115,523	1,078	493	(25,939)	91,155

The notes following the financial statements form part of the financial report.

Statement of cash flows

CONSOLIDATED	Note	31 Dec 2023 \$000	31 Dec 2022 \$000
Cash flows from operating activities			
Receipts from customers		15,105	18,819
Payments to suppliers and employees		(26,505)	(23,753)
Income tax paid		-	-
Interest received		30	43
Finance costs		(52)	(64)
Net cash (outflow) from operating activities		(11,422)	(4,955)
Cash flows from investing activities			
Payments for plant and equipment		(45)	(293)
Payment for purchase of business, net of cash acquired		-	-
Net cash (used) for investing activities		(45)	(293)
Cash flows from financing activities			
Proceeds from issues of equity securities		5,403	-
Transaction costs related to issues of equity securities		(391)	-
Repayment of principal on lease liabilities		(328)	(303)
Net cash (outflows)/inflows from financing activities		4,684	(303)
Net (decrease) in cash and cash equivalents		(6,783)	(5,551)
Effects of exchange rate changes on cash and cash equivalents		56	80
Cash and cash equivalents at the beginning of the period		14,641	17,339
Cash and cash equivalents at the end of the period		7,914	11,868

The notes following the financial statements form part of the financial report.

Notes to the financial statements

1. General information

Alcidion Group Limited (“Alcidion” or the “Group” or the “Company”) is a limited company incorporated in Australia. The core of Alcidion’s business model is to create intellectual property in the form of Clinical Information System software developed to improve the quality of care for all patients and improve the productivity of clinicians and care teams.

The Company’s software is bundled with other technologies and services to create complete clinical and business solutions for healthcare providers. Alcidion builds, sells, delivers, hosts and supports solutions for health care provider organisations in Australia, New Zealand and the United Kingdom.

2. Statement of material accounting policies

These consolidated financial statements are general purpose interim financial statements which have been prepared in accordance with the Corporations Act 2001, and Australian Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’

This interim financial report is intended to provide users with an update on the latest annual financial statements of the Group. As such, it does not contain information that represents relatively immaterial changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2023, together with any public announcements made during the half year.

The half-year financial statements were authorised for issue by the directors on 28 February 2024.

2.1 Basis of preparation

The financial statements comprise the consolidated financial statements of the Group which comprises the Company and its legal subsidiaries. For the purposes of preparing the consolidated financial statements, the Group is a for-profit entity. Except for the changes disclosed at Note 2.2 below, the same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent financial statements.

The condensed interim financial consolidated financial statements of the Group are for the six months ended 31 December 2023 and are presented in Australian Dollars (\$), which is the functional currency of the Parent Company.

2.2 New or amended accounting standard and interpretations adopted

The Group has adopted all new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. There has been no impact from this adoption.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been adopted early.

3. Depreciation and amortisation

	31 Dec 2023	31 Dec 2022
	\$000	\$000
Depreciation of plant and equipment	215	160
Depreciation of right of use assets	416	402
Amortisation of intangible assets	1,001	980
Total Depreciation and amortisation	1,632	1,542

4. Trade and other receivables

	31 Dec 2023 \$000	30 June 2023 \$000
Trade receivables	7,254	3,304
Accrued income	1,203	1,431
	8,457	4,735

5. Intangible assets

	Goodwill \$000	Customer contracts \$000	Acquired Software \$000	Patents & Trademarks \$000	Total \$000
Cost					
At 1 July 2022	67,763	15,595	16,399	341	100,098
Additions	-	-	-	-	-
At 30 June 2023	67,763	15,595	16,399	341	100,098
At 1 July 2023	67,763	15,595	16,399	341	100,098
Additions	-	-	-	-	-
At 31 December 2023	67,763	15,595	16,399	341	100,098
Accumulated amortisation					
At 1 July 2022	-	859	378	37	1,274
Reallocation	-	(481)	481	-	-
Amortisation expense	-	558	1,373	60	1,991
At 30 June 2023	-	936	2,232	97	3,265
At 1 July 2023	-	936	2,232	97	3,265
Amortisation expense	-	283	687	31	1,001
At 31 December 2023	-	1,219	2,919	128	4,266
Carrying value					
At 30 June 2023	67,763	14,659	14,167	244	96,833
At 31 December 2023	67,763	14,376	13,480	213	95,832

6. Issued capital

Consolidated	6 Months to 31 December 2023		12 months to 30 June 2023	
	No.	\$000	No.	\$000
Opening balance	1,268,069,053	110,511	1,268,069,053	110,511
Shares issued during the period:				
Performance rights vested	2,364,226	-	-	-
Placement/SPP	72,039,942	5,012	-	-
Closing balance	1,342,473,221	115,523	1,268,069,053	110,511

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

7. Dividends

There were no dividends paid or proposed during the period.

8. Loss per share

Earnings (loss) per share	31 Dec 2023 Cents	31 Dec 2022 Cents
Basic and diluted earnings (loss) per share	(0.34)	(0.22)

(a) Earnings used in calculating basic and diluted earnings per share

	31 Dec 2023 \$000	31 Dec 2022 \$000
(Loss) attributable to ordinary shareholders of the Group used in calculating basic and diluted earnings (loss) per share	(4,366)	(2,842)

(b) Weighted average number of shares used as denominator to calculate basic and diluted earnings per share

	December 2023 No.	December 2022 No.
Weighted average number of ordinary shares used in calculating basic & diluted earnings per share	1,290,363,574	1,268,069,053

9. Commitments

As at 31 December 2023 the Group has no commitments (30 June 2023: nil)

10. Contingencies

In the opinion of the Directors, the Group did not have any contingent liabilities or contingent assets as at 31 December 2023 (30 June 2023: nil).

11. Segment reporting

The Group operates in the healthcare industry in Australia, New Zealand and the UK. For management purposes, the Group is organised into one main operating segment which involves the provision of healthcare software solutions in all these territories. All the Group's activities are inter-related and financial information is reported to the Board (Chief Operating Decision Maker) as a single segment. All significant operating decisions are based upon analysis of the Group as one segment. The financial results of this segment are therefore equivalent to the financial statements of the Group.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors, being the chief operating decision makers with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

Intersegment transactions

There were no intersegment sales during the period.

Segment information

Group Performance - No separate Group performance has been presented in this report as the Board receives only a consolidated Group performance report which is the equivalent to the statement of Profit or Loss and Other Comprehensive Income of the Group as a whole.

Group assets and liabilities - No separate Group asset and liabilities have been presented in this report as the Board only receives a consolidated asset and liabilities report which is the equivalent to the statement of financial position of the Group as a whole.

Revenue by geographical region	31 Dec 2023		31 Dec 2022	
	\$000	%	\$000	%
Australia / New Zealand	11,021	58%	10,236	54%
United Kingdom	8,038	42%	8,748	46%
Total revenue	19,059		18,984	

Timing of revenue recognition	31 Dec 2023			31 Dec 2022		
	\$000			\$000		
	Goods transferred at a point in time	Service transferred over time	Total	Goods transferred at a point in time	Service transferred over time	Total
Australia / New Zealand	6,848	4,173	11,021	6,271	3,965	10,236
United Kingdom	7,197	841	8,038	7,585	1,163	8,748
Total revenue	14,045	5,014	19,059	13,856	5,128	18,984

Major customers

During the period the group had one customer that individually accounts for more than 10% of revenue:

- Leidos Australia \$5,860K (30.7 %) (Dec 22: \$3,987K (21.0%))

12. Events after the end of the interim period

No matter or circumstances have arisen since the end of the half-year reporting period which significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future years.

Directors' declaration

The directors declare that:

- a) in the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Group for the half year ended 31 December 2023.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the Directors



Rebecca Wilson
Non-Executive Chair
Melbourne, 28 February 2024

Independent Auditor's Review Report



Independent auditor's review report to the members of Alcidion Group Limited

Report on the half-year financial report



Our conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Alcidion Group Limited (the Company), and its subsidiaries (the Group) does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 31 December 2023 and of its financial performance for the half-year then ended; and
- complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

What was reviewed?

We have reviewed the accompanying half-year financial report of the Group, which comprises:

- the consolidated statement of financial position as at 31 December 2023,
- the consolidated statement of profit or loss and other comprehensive income for the half-year then ended,
- the consolidated statement of changes in equity for the half-year then ended,
- the consolidated statement of cash flows for the half-year then ended,
- notes to the financial statements, including a statement of material accounting policies and other explanatory information, and
- the directors' declaration.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Independent Auditor's Review Report

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2023 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



William Buck (SA)
ABN: 38 280 203 274



G.W. Martinella
Partner

Dated this 28th day of February, 2024.

Corporate Directory

Current Directors (Alcidion Group Limited)

Name	Position	Date of Appointment
Ms Rebecca Wilson	Non-Executive Chair	01/08/2017
Ms Kate Quirke	Managing Director	03/07/2018
Mr Simon Chamberlain	Non-Executive Director	01/07/2019
Ms Victoria Weekes	Non-Executive Director	01/09/2021
Mr Daniel Sharp	Non-Executive Director	01/09/2021
Ms Melanie Leydin	Company Secretary	04/03/2019

Registered office

Level 4
100 Albert Road
South Melbourne VIC 3205

Principal place of business

Level 10
9 Yarra Street
South Yarra VIC 3141
☎ 1800 767 873

Website

www.alcidion.com

Registers of securities

Computershare Investor Services Pty Ltd
Level 5, 115 Grenfell Street,
Adelaide SA 5000

Auditors

William Buck
Level 6, 211 Victoria Square
Adelaide SA 5000

☎ +61 8 8409 4333

☎ +61 8 8409 4499

Stock Exchange

Australian Securities Exchange Limited
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

ASX Code: **ALC**

DSG

Castle Chambers, 43 Castle Street
Liverpool L2 9TL
England UK

☎ +44 151 294 5400

Tax Accountants

BDO
Level 11, 1 Margaret St
Sydney, NSW, 2000

☎ +61 2 9251 4100

Bankers

Westpac Banking Corporation
Level 30, 275 Kent Street
Sydney, NSW, 2000

☎ 1300 134 291



ABOUT ALCIDION

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2024. Alcidion, Miya Precision, Patienttrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

www.alcidion.com
investor@alcidion.com

Head Office

Level 10, 9 Yarra Street
SOUTH YARRA VIC 3141
AUSTRALIA
P 1800 767 873